Pulmonology

Many studies have already shown that short-term exposure to fine particle pollution can have a negative effect on lung function, but just 2 exist on the long-term effects, with inconsistent results.

The U.S. FDA granted Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease (SSc-ILD).

The anti-inflammatory proved superior to as-need bronchodilator for control of early stage asthma symptoms in preschool children.

Psychological stress-induced alterations of the neuroendocrine-immune system in allergic airway inflammation suggest a novel phenotype in asthma.

New research indicates overweight patients may have worse asthma control outcomes after a year of subcutaneous immunotherapy than their normal weight counterparts.

This morning, Alynylam Pharmaceuticals, Inc. has announced the Bridge the Gap initiative in which it will partner with a family affected by hATTR amyloidosis for a new book. The initiative, called , will allow the family that has lived with the rare disease for generations to share its personal accounts. The book is titled “Living a Rare Life,” and can be found, along with other educational content, at hATTRBridge.com.

While some studies have shown that steroids helped resolve sore throats faster, others have indicated that steroids show no effectiveness for sinusitis or bronchitis.

Virtually all deaths from RSV occur in developing countries, and long-term airway morbidity should be studied in those parts of the world.

Multiple studies have previously shown that increases in cockroach allergen are linked to a four-fold risk of asthma.

As the use of e-cigarettes increases in the US, allergists and pulmonologists should ensure they educate their patients about the risks.

Oral immunotherapy appears to be particularly promising and has strong potential for anaphylaxis protection when administered by protocol.

The EpiPen4Schools program survey found 1140 anaphylactic reactions were reported from 2013 to 2014. No treatment was given in 2% of anaphylaxis.

After a thorough analysis of all controlled studies, no strong clinically significant evidence was observed for any individual or multicomponent intervention.

While advances have been made in understanding EoE, most studies have been descriptive and our understanding of the etiology of EoE remains elusive.

Researchers agree the telemedicine is empowering physicians to more efficiently and conveniently handle patients, and is expected to provide increasingly demonstrable positive therapeutic benefits

Mepolizumab reduced Asthma Control Questionnaire scores from baseline by –1.45 in patients that had uncontrolled asthma with omalizumab.

KIT inhibition with imatinib reduced mast cells in patients with severe asthma in a proof-of-concept trial, but is the treatment feasible for the future?